IMW 2021 | Sequencing BCMA-targeted therapies in myeloma
Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, talks on the sequencing of B-cell maturation antigen (BCMA)-targeting agents such as antibody-drug conjugates, bispecifics antibodies and chimeric antigen receptor T-cell (CAR-T) therapy. Prof. van de Donk reports that prior BCMA-targeted therapy may impact BCMA expression and therefore recommends having an intermittent line of therapy before going on to another BCMA-targeting therapy where possible. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Niels van de Donk, MD, PhD, has received research support from Janssen Pharmaceuticals, AMGEN, Celgene, Novartis and BMS; and serves in advisory boards for Janssen Pharmaceuticals, AMGEN, Celgene, BMS, Takeda, Roche, Novartis, Bayer, and Servier.
